Author Archives: Ana Belo van Wijk, PhD

Xeljanz Shows Promise for Ankylosing Spondylitis in Phase 2 Trial

Xeljanz (tofacitinib) showed promising results for ankylosing spondylitis (AS) patients in a 16-week Phase 2 clinical trial. AS patients with active disease receiving Xeljanz treatment showed great improvement in symptoms and clinical disease profiles when compared to patients treated with placebo. The study, “Tofacitinib in patients with ankylosing…